An Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of ILV-094 Administered Subcutaneously or Intravenously to Subjects With Psoriasis.

Trial Profile

An Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of ILV-094 Administered Subcutaneously or Intravenously to Subjects With Psoriasis.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2011

At a glance

  • Drugs Fezakinumab; Fezakinumab
  • Indications Psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2011 Additional location (South Africa) added as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Pfizer added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top